Johnson & Johnson Just Got a Big FDA Win
Key Points
Imaavy can be used to treat patients aged 12 and older with warm autoimmune hemolytic anemia (wAIHA), a rare blood disease.
It's the second FDA win for JNJ in as many months.
- 10 stocks we like better than Johnson & Johnson ›
Healthcare giant Johnson & Johnson (NYSE: JNJ) racked up another win this week from the U.S. Food and Drug Administration.
The regulator approved JNJ's drug Imaavy to treat patients 12 and older who have a rare life-threatening condition called warm autoimmune hemolytic anemia (wAIHA), in which autoantibodies attack red blood cells, leading to severe anemia and fatigue. Between one and three new people per 100,000 are affected by wAIHA each year, and about 1 in 8,000 people live with the condition, according to JNJ.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
It's the second FDA win in as many months for JNJ. In July, the company won FDA approval for its dual-energy ablation catheter, which can deliver radiofrequency and pulsed field energy to treat atrial fibrillation, a common heart rhythm disorder.
Johnson & Johnson, of course, is a household name in the U.S., as its products -- from baby powder to Band-Aids -- are well known in every American household. The company spun off the consumer business in 2023 and now operates two major divisions: medical technology equipment and pharmaceuticals.
It's done very well in recent years. As a result, JNJ's share price is up 51% over the past 52 weeks, significantly outperforming the broader market, which is up about 19% over that time, as measured by the S&P 500 index.
Should you buy stock in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,461!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,307,633!*
Now, it’s worth noting Stock Advisor’s total average return is 973% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 27, 2026.
Matthew Benjamin has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
Recommended Articles
